Annexin Pharmaceuticals AB (publ)

Annexin Pharmaceuticals AB (publ) is a biotechnology company headquartered in Stockholm, Sweden, established in 2014. The company focuses on developing ANXV, a drug candidate based on recombinant Annexin A5 protein, designed to treat a variety of cardiovascular and inflammatory diseases by protecting and repairing blood vessels and modulating immune responses. ANXV acts by binding phosphatidylserine, a lipid exposed on stressed or damaged cells, which helps control inflammation and tissue injury. Annexin Pharmaceuticals holds a strong patent portfolio covering the drug’s production process and therapeutic uses, aiming to address significant unmet medical needs in indications such as retinal vein occlusion and cancer. With a research-driven approach, the company is conducting clinical trials to evaluate ANXV’s efficacy and safety, positioning itself as a leader in the Annexin A5 biological area within the pharmaceutical and biotech sector.